Adverse events of raltegravir and dolutegravir

Luigia Elzi, Stefan Erb, Hansjakob Furrer, Matthias Cavassini, Alexandra Calmy, Pietro Vernazza, Huldrych Günthard, Enos Bernasconi, Manuel Battegay, Swiss HIV Cohort Study Group, Luigia Elzi, Stefan Erb, Hansjakob Furrer, Matthias Cavassini, Alexandra Calmy, Pietro Vernazza, Huldrych Günthard, Enos Bernasconi, Manuel Battegay, Swiss HIV Cohort Study Group

Abstract

Objective: To compare the frequency and risk factors of toxicity-related treatment discontinuations between raltegravir and dolutegravir.

Design: Prospective cohort study.

Methods: All antiretroviral therapy (ART)-naïve and ART-experienced HIV-infected individuals from the Swiss HIV Cohort Study who initiated raltegravir or dolutegravir between 2006 and 2015 were investigated concerning treatment modification within the first year.

Results: Of 4041 patients initiating ART containing raltegravir (n = 2091) or dolutegravir (n = 1950), 568 patients discontinued ART during the first year, corresponding to a rate of 15.5 [95% confidence interval (CI) 14.5-16.9] discontinuations per 100 patient-years. Only 10 patients on raltegravir (0.5%) and two patients on dolutegravir (0.1%) demonstrated virologic failure. The main reason for ART discontinuation was convenience expressed as patient's wish, physician's decision, or treatment simplification (n = 302). Toxicity occurred in 4.3% of patients treated with raltegravir and 3.6% with dolutegravir, respectively. In multivariable analysis, the only independent risk factor for discontinuing ART because of toxicity was female sex (hazard ratio 1.98, 95% CI 1.45-2.71, P < 0.001).Neuropsychiatric complaints were the most commonly reported toxic adverse events and more frequent in the dolutegravir (n = 33, 1.7%) compared with the raltegravir group (n = 13, 0.6%). Risk of discontinuation for neurotoxicity was lower for raltegravir than for dolutegravir in multivariable analysis (hazard ratio 0.46, 95% CI 0.22-0.96, P = 0.037).

Conclusion: In this, large cohort raltegravir and dolutegravir-containing regimen demonstrated a high virologic efficacy. Drug toxicity was infrequent and discontinuation because of neuropsychiatric events within the first year of treatment was only marginal higher with dolutegravir compared with raltegravir. However, monitoring of neurotoxic side-effects of dolutegravir is important.

References

    1. EACS. European AIDS Clinical Society: EACS Guidelines 8.2. In: EACS Guidelines 82: European AIDS Clinical Society; 2017
    1. Gunthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the international antiviral society-USA panel. JAMA 2016; 316:191–210.
    1. Podany AT, Scarsi KK, Fletcher CV. Comparative clinical pharmacokinetics and pharmacodynamics of HIV-1 integrase strand transfer inhibitors. Clinical Pharmacokinet 2017; 56:25–40.
    1. Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, et al. SPRING-2 Study Group. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013; 381:735–743.
    1. Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, et al. ING114915 Study Team. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 2014; 383:2222–2231.
    1. Raffi F, Rachlis A, Brinson C, Arasteh K, Gorgolas M, Brennan C, et al. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials. AIDS 2015; 29:167–174.
    1. de Boer MG, van den Berk GE, van Holten N, Oryszcyn JE, Dorama W, Moha DA, Brinkman K. Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice. AIDS 2016; 30:2831–2834.
    1. Kheloufi F, Allemand J, Mokhtari S, Default A. Psychiatric disorders after starting dolutegravir: report of four cases. AIDS 2015; 29:1723–1725.
    1. Hoffmann C, Welz T, Sabranski M, Kolb M, Wolf E, Stellbrink HJ, Wyen C. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med 2017; 18:56–63.
    1. Kirby C, Ovens K, Shaw M, Harweir V, Gilleece Y, Churchill D. Adverse events of dolutegravir may be higher in real world settings. In: 22nd Annual Conference of the British HIV Association (BHIVA). Manchester, UK: HIVMed; 2016. pp. 22–23
    1. Llibre JM, Esteve A, Miro JP, Mateo G, Curran A, Podzamczer D, et al. Discontinuation of DTG, EVG/c, and RAL due to toxicity in a prospective cohort. In: Conference on Retroviruses and Opportunistic Infections CROI. Seattle; 2017
    1. Hsu R, Fusco J, Henegar C, Carpio F, Mounzer K, Wohlfeiler M, et al. Psychiatric Disorders Observed in HIV+ Patients Using 6 Common 3rd Agents in OPERA. In: Conference on Retroviruses and Opportunistic Infections CROI. Seattle; 2017
    1. Yagura H, Watanabe D, Nakauchi T, Tomishima K, Kasai D, Nishida Y, et al. Effect of Dolutegravir plasma concentration on central nervous system side effect. In: Conference on Retroviruses and Opportunistic Infections CROI. Seattle; 2017

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する